Hansa Biopharma AB (publ)
HNSBF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $254 | $2,004 | $2,042 | $2,251 |
| - Cash | $27 | $354 | $250 | $405 |
| + Debt | $98 | $906 | $1,018 | $1,079 |
| Enterprise Value | $325 | $2,556 | $2,810 | $2,924 |
| Revenue | $3 | $49 | $66 | $32 |
| % Growth | -93.4% | -26% | 105.2% | – |
| Gross Profit | $1 | $31 | $46 | $19 |
| % Margin | 34.7% | 62.8% | 69.1% | 58.3% |
| EBITDA | -$15 | -$165 | -$7 | -$170 |
| % Margin | -445.8% | -335.3% | -10.9% | -525.2% |
| Net Income | -$16 | -$179 | -$37 | -$276 |
| % Margin | -481.3% | -364.2% | -55.9% | -854.8% |
| EPS Diluted | -0.19 | -2.53 | -0.55 | -4.08 |
| % Growth | 92.5% | -360% | 86.5% | – |
| Operating Cash Flow | -$9 | -$112 | -$152 | -$207 |
| Capital Expenditures | $0 | $0 | -$1 | $0 |
| Free Cash Flow | -$9 | -$112 | -$153 | -$207 |